Latest Insider Positions

GROENHUYSEN WILHELMUS CM is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Peers of GROENHUYSEN WILHELMUS CM include the following: Ambrogi Michael J., Avista Capital Partners (Offshore) II, L.P., Avista Capital Partners (Offshore) II-A, LP, Avista Capital Partners II GP, LLC, Avista Capital Partners II, L.P., Bierly Rick, Bradshaw Paul, Burkoth William T., DOYLE WILLIAM F, Danziger Asaf, Entrepreneurs Fund General Partner Ltd, Entrepreneurs Fund LP, FUTRELL STEVE, GRANOFF MICHAEL D, Gibbs Thomas Edward, Goldan Keith A., JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Mahmoud Ramy A, Marino Michael F III, Melnyk Peter M., Miller Peter K, PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pickering Larry G, Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, Scodari Joseph C, TKWD Ventures LLC, VERNON W ANTHONY, Venkataraman Sriram, Volati Ltd, WFD Ventures Fund II, L.P., WFD Ventures LLC, Wyss Hansjoerg, . Peers are determined by cross-linking the filings of GROENHUYSEN WILHELMUS CM with insider filings of others at the same companies.

Click the link icon to see the full transaction history.

Tran Date
Security Code Shares Post Shares Percent
2018-01-09 NVCR / NovoCure Chief Financial Officer S -31,132 209,078 -12.96 21.0194 -654,376 4,394,694 -14.89
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

More Health Care Catalysts to Watch For by the End of February

6h 247wallst
Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But consider that with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (52-0)

JF's Core Biotech Buys Edition 1 Volume 3: 2 New Purchases, Plus Thoughts On Portfolio Management And Performance

10h seekingalpha
For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio. (279-0)

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

JF's Core Biotech Buys: Edition 1 Volume 1

2018-02-05 seekingalpha
This is a reboot of a prior series that readers have requested for some time (apologies for taking so long to get back with a solution). (44-1)

Seattle Genetics: A Buy After Brilliant Acquisition

2018-02-03 seekingalpha
Shares have risen by over 75% during the past three years, yet floundered over the past 12 months or so. (130-2)

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

2018-02-02 seekingalpha
I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY. (539-1)

ROTY Edition 1 Volume 71: Thoughts On A Juno Buyout, Outperformance Continues And Other Updates

2018-01-19 seekingalpha
A buyout of Juno Therapeutics would likely provide a boost to the biotech sector if it actually occurs. (372-1)

Novocure: Recent Developments And Upcoming Prospects In Mesothelioma

2018-01-12 seekingalpha
Tumor Treating Fields aims next at increasing overall survival in Mesothelioma patients. We explore its prospects. (34-1)

NovoCure: 2018 Looks Good After A Great 2017

2018-01-10 seekingalpha
Growth, real operating leverage and great research results provide a myriad of triggers for the stock. (3-0)

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

2018-01-09 seekingalpha
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-6)